Press Releases April 16, 2026 08:00 PM

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

Surgery Partners Announces Q1 2026 Earnings Release Date and Conference Call

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
SGRY

Surgery Partners, Inc., a leading outpatient surgical services provider, announced that it will release its first quarter 2026 earnings before market open on May 5, 2026, followed by a conference call the same day. The company provides high-quality, cost-effective surgical and ancillary care through over 200 locations in 30 states.

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
SGRY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release scheduled for May 5, 2026, before market opens.
  • Conference call details provided with dial-in numbers and webcast link.
  • Surgery Partners operates a differentiated outpatient delivery model across multiple healthcare facilities nationwide.

BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2026 results before the market opens on Tuesday, May 5, 2026, to be followed by a conference call at 8:30 a.m. (Eastern Time).

You can join the call as follows:

  • Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)
  • Replay (available 3 hours after the call and available until May 19, 2026): 1-844-512-2921 (domestic), 1-412-317-6671 (international)
  • Passcode for the live call and the replay: 13760194

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at www.surgerypartners.com. The replay will also be available on this same website for a limited time following the call.

To learn more about Surgery Partners, please visit the company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution of material company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible. 

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

Contact:

Surgery Partners Investor Relations
(615) 234-8940
[email protected]


Risks

  • Potential uncertainty in earnings performance impacting stock price post-release.
  • Healthcare sector regulatory changes affecting outpatient surgery operations.
  • Market reaction depends on financial results which are yet unknown.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026